Information de reference pour ce titreAccession Number: | 00000465-200112000-00010.
|
Author: | Marshall, Randall D. M.D.; Beebe, Katherine L. Ph.D.; Oldham, Mary Ph.D.; Zaninelli, Rocco M.D.
|
Institution: | From the New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons; GlaxoSmithKline, Research and Development, Collegeville, Pa.; and Biostatistics and Data Sciences, Harlow, U.K.
|
Title: | Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study.[Article]
|
Source: | American Journal of Psychiatry. 158(12):1982-1988, December 2001.
|
Abstract: | Objective: This study evaluated the efficacy and safety of paroxetine for the treatment of patients with chronic posttraumatic stress disorder (PTSD).
Method: Outpatients with chronic PTSD according to DSM-IV criteria and a score of 50 or more on the Clinician-Administered PTSD Scale, part 2, were randomly assigned to take placebo (N=186), 20 mg/day of paroxetine (N=183), or 40 mg/day of paroxetine (N=182) for 12 weeks. Efficacy was assessed by examining the change in total score from baseline to endpoint on the Clinician-Administered PTSD Scale, part 2, and rates of response ("very much improved" or "much improved") for global improvement on the Clinical Global Impression scale.
Results: Paroxetine-treated patients in both dose groups demonstrated significantly greater improvement on primary outcome measures compared to placebo-treated patients in the intent-to-treat analysis. Moreover, paroxetine treatment resulted in statistically significant improvement compared to placebo on all three PTSD symptom clusters (reexperiencing, avoidance/numbing, and hyperarousal), social and occupational impairment, and comorbid depression. Paroxetine was effective for both men and women. Treatment response did not vary by trauma type, time since trauma, or severity of baseline PTSD or depressive symptoms. Both doses were well tolerated.
Conclusions: Doses of 20 and 40 mg/day of paroxetine are effective and well tolerated in the treatment of adults with chronic PTSD.
Copyright (C) 2001 American Psychiatric Association.
|
References: | 1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB: Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048-1060
2. Davidson JRT, Hughes D, Blazer D, George LK: Posttraumatic stress disorder in the community: an epidemiological study. Psychol Med 1991; 21:1-19
3. Blanchard EB, Buckley TC, Hickling EJ, Taylor AE: Posttraumatic stress disorder and comorbid major depression: is the correlation an illusion? J Anxiety Disord 1998; 12:21-37
4. Wagner D, Heinrichs M, Ehlert U: Prevalence of symptoms of posttraumatic stress disorder in German professional firefighters. Am J Psychiatry 1998; 155:1727-1732
5. Ferrada-Noli M, Asberg M, Ormstad K, Lundin T, Sundbom E: Suicidal behavior after severe trauma, part 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior. J Trauma Stress 1998; 11:103-112
6. McFarlane AC, Atchison M, Rafalowicz E, Papay P: Physical symptoms in posttraumatic stress disorder. J Psychosom Res 1994; 38:715-726
7. Heim C, Ehlert U, Hellhammer DH: The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 2000; 25:1-35
8. Charney DS, Bremner JD: The neurobiology of anxiety disorders, in Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York, Oxford University Press, 1999, pp 494-517
9. Yehuda R: Cortisol alterations in PTSD, in International Handbook of Human Response to Trauma. Edited by Yehuda R, Shalev A, McFarlane A. New York, Kluwer Academic/Plenum, 2000, pp 265-283
10. Southwick SM, Krystal JH, Bremner JD, Morgan CA, Nicolaou AL, Nagy LK, Johnson DR, Heninger GR, Charney DS: Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1997; 54:749-758
11. Kent JM, Coplan JD, Gorman JM: Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998; 44:812-824
12. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HR Jr: The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572:117-125
13. Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F: Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994; 50:509-519
14. Graham YP, Heim C, Goodman SH, Miller AH, Nemeroff CB: The effects of neonatal stress on brain development: implications for psychopathology. Dev Psychopathol 1999; 11:545-565
15. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179:366-370
16. Frank JB, Kosten TR, Giller EL, Dan E: A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988; 145:1289-1291
17. Van der Kolk BA, Dreyfull D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55:517-522
18. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JRT: Fluoxetine in posttraumatic stress disorder: randomized, double-blind study. Br J Psychiatry 1999; 175:17-22
19. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA 2000; 283:1837-1844
20. Dunbar GC, Fuell DL: The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992; 6:81-90
21. Marshall RD, Schneier FR, Knight CBG, Abbate LA, Fallon BA, Goetz D, Campeas R, Liebowitz MR: An open trial of paroxetine in patients with noncombat-related chronic PTSD. J Clin Psychopharmacol 1998; 18:10-18
22. Weathers FW, Keane TM, Davidson JRT: Clinician-Administered PTSD Scale: a review of the first ten years of research. Depress Anxiety 2001; 13:132-156
23. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC: The Mini International Neuropsychiatric Interview (MINI): a short diagnostic structure interview: reliability and validity according to the CIDI. Eur Psychiatry 1997; 12:224-231
24. Davidson JRT, Book SW, Colket JT, Tupler LA, Roth S, David D, Hertzeberg M, Mellman T, Beckham JC, Smith RD, Davison RM, Katz R, Feldman ME: Assessment of a new self-rating scale for posttraumatic stress disorder. Psychol Med 1997; 27:153-160
25. Connor KM, Davidson JRT: Further psychometric assessment of the TOP-8: a brief interview-based measure of PTSD. Depress Anxiety 1999; 9:135-137
26. Sheehan DV, Harnett-Sheehan K, Raj BA: The measurement of disability. Int Clin Psychopharmacol 1996; 11:89-95
27. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
28. Draper NR, Smith H: Applied Regression. New York, John Wiley & Sons, 1981
29. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-802
30. Cox DR, Snell EJ: Analysis of Binary Data. London, Chapman & Hall, 1970
31. Sprent P: Applied Non-Parametric Statistical Methods. London, Chapman & Hall, 1989
32. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia. JAMA 1998; 280:708-713
33. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88:1-11
34. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155:36-42
35. Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996; 169:468-474
36. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JRT: Lack of efficacy for fluoxetine in PTSD: a placebo-controlled trial in combat veterans. Ann Clin Psychiatry 2000; 12:101-105
37. Marshall RD, Cloitre M: Maximizing treatment outcome in PTSD by combining psychotherapy with pharmacotherapy. Curr Psychiatry Rep 2000; 2:335-340
38. Foa EB, Dancu DV, Hembree EA, Jaycox LH, Meadows EA, Street GP: A comparison of exposure therapy, stress inoculation training and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol 1999; 67:194-200
39. Jaycox LH, Foa EB: Obstacles in implementing exposure therapy for PTSD: case discussions and practical solutions. Clin Psychol Psychother 1996; 3:176-184
|
Language: | English.
|
Document Type: | New Research: Article.
|
Journal Subset: | Clinical Medicine. Behavioral & Social Sciences.
|
ISSN: | 0002-953X
|
NLM Journal Code: | 0370512, 3vg
|
Annotation(s) | |
|
|